LivaNova (LIVN) Expected to Announce Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) will likely be issuing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect LivaNova to post earnings of $0.80 per share and revenue of $354.3120 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

LivaNova Stock Up 1.8%

Shares of NASDAQ:LIVN opened at $66.96 on Wednesday. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. The stock has a fifty day simple moving average of $63.78 and a two-hundred day simple moving average of $57.95. LivaNova has a 12-month low of $32.48 and a 12-month high of $67.92. The stock has a market capitalization of $3.66 billion, a price-to-earnings ratio of -16.74 and a beta of 0.97.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its holdings in shares of LivaNova by 22.4% in the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after buying an additional 544,033 shares in the last quarter. Wellington Management Group LLP increased its holdings in LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after acquiring an additional 1,067,349 shares during the last quarter. AQR Capital Management LLC lifted its stake in LivaNova by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock worth $132,606,000 after purchasing an additional 496,165 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in LivaNova by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,787,928 shares of the company’s stock worth $110,014,000 after purchasing an additional 66,755 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of LivaNova by 1.5% during the 3rd quarter. Invesco Ltd. now owns 1,043,763 shares of the company’s stock valued at $54,672,000 after purchasing an additional 15,050 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LIVN has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Robert W. Baird set a $75.00 target price on shares of LivaNova in a report on Tuesday, December 16th. Barclays increased their price target on shares of LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a report on Friday, January 9th. Mizuho boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $69.38.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.